Cytotoxics and High Potency Manufacturing
- All
- APIs
- Aseptic Processing
- cGMP Manufacture
- Cleaning Validation
- Clinical Trial Materials
- Cytotoxics and High Potency Manufacturing
- Excipients
- Extractables and Leachables
- Facilities
- Fill/Finish
- Lyophilization
- Parenterals
- Process Development
- Process Validation
- Risk Management
- Scale-up/Technology Transfer
- Solid Dosage/Creams/Ointments
-
Cytotoxics and High Potency Manufacturing
HPAPI Drug Manufacturing Trends
Managing accelerated timelines in manufacturing high-potency drugsMaurits Janssen, Head of Commercial Development, Lonza Pharma & Biotech 05.05.20
-
Cytotoxics and High Potency Manufacturing | Fill/Finish | Information Technology
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
Piramal to Expand Aurora Facility
To add 10,500 sq.-ft. state-of-the-art wing dedicated to manufacturing Active Pharmaceutical Ingredients01.28.20
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing
HPAPI Market Trends: PCI Expands Capabilities
Michael Ellingson of PCI discusses market demand for specialty drug product capabilities and the Rockford, IL expansionOnline Exclusives Kristin Brooks, Cotract Pharma 01.10.20
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
-
APIs | Cytotoxics and High Potency Manufacturing | Facilities
Flamma Arrives in the U.S.
Italian CDMO sets down roots in the U.S. market with purchase of Teva facility.Tim Wright, Editor, Contract Pharma 10.15.19
-
Cytotoxics and High Potency Manufacturing
-
Cytotoxics and High Potency Manufacturing
High Containment & Cost Savings with Single Use Isolator Technology
The trend towards HPAPIs is driving the need for innovative containment systems.Scott Patterson, Vice President Commercial Sales, ILC Dover 09.16.19
-
Cytotoxics and High Potency Manufacturing
Handling & Assessing HPAPIs
As oncology pipelines grow, so too is the demand for highly potent materials, which require careful handling and containment.Jason Korbel, Technical Services Manager, Cambrex Charles City 09.16.19
-
Cytotoxics and High Potency Manufacturing
API to ADC: A Journey Through High Potency
This class of compounds represents a major advance in oncology research and treatment application.Maurits Janssen, Head Commercial Development API, Lonza Pharma & Biotech 09.16.19
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Piramal Invests $10 million in Riverview Expansion
Expands High Potency API Capability to serve the growing ADC market06.21.19
-
Bio News | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Lonza to Expand HPAPI Development and Manufacturing Capacity
Will develop new facilities at Visp site; enters long term mfg. agreement with AstraZeneca06.14.19
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Cambrex Completes Highly Potent API Mfg. Site
Investment in Charles City, IA site totaled $24 million04.11.19
-
APIs | Cytotoxics and High Potency Manufacturing
The Embedded CDMO
Pfizer CentreOne’s JoyL Silva talks about the advantages of being parked inside PfizerTim Wright, Editor, Contract Pharma 04.05.19
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
PCI Invests in High Potent Tableting and Powder Modification Capacity
Investment in Tredegar, Wales site to double highly potent tableting capacity and boost powder handling capability03.27.19
-
Cytotoxics and High Potency Manufacturing
High Containment & Cost Savings with Single Use Isolator Technology
The trend towards HPAPIs is driving the need for innovative containment systems.Online Exclusives Scott Patterson, Vice President Commercial Sales, ILC Dover 01.31.19
-
APIs | Cytotoxics and High Potency Manufacturing | Drug Development
CDMOs On The Rise
Tracking growth and strategies in the CDMO businessMichel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Baxter, Oasmia Ink Apealea Commercial Mfg. Pact
Apealea will be manufactured at Baxter’s cytotoxic manufacturing site in Germany12.07.18
-
Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News | Inspections | QA/QC | Regulatory Affairs
Recipharm Audit Results in Licence Restriction
Five non-critical highly potent products from the Ashton-u-Lyne, UK site suspended due to potential cross contamination risk10.25.18
